Patents by Inventor Andreas Raschig

Andreas Raschig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of type 2 diabetes
    Patent number: 8202884
    Abstract: The invention relates to the use of a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for the manufacture of a medicament for the treatment of diabetic patients.
    Type: Grant
    Filed: October 31, 2006
    Date of Patent: June 19, 2012
    Assignee: Neurosearch A/S
    Inventors: Klaus Dugi, Andreas Raschig, Juergen Reess, Frank Berger, Laurence Salin
  • PHARMACEUTICAL COMPOSITION COMPRISING A MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITOR AND AN ACETYLCHOLINESTERASE INHIBITOR
    Publication number: 20100210626
    Abstract: The invention relates to a pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof (1), and at least one acetylcholinesterase inhibitor or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof (2), and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.
    Type: Application
    Filed: April 27, 2010
    Publication date: August 19, 2010
    Inventors: Thomas FRIEDL, Joachim MIERAU, Andreas RASCHIG, Juergen REESS, Joergen SCHEEL-KRUEGER
  • Treatment of Diabetes
    Publication number: 20090018159
    Abstract: The invention relates to the use of a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for the manufacture of a medicament for the treatment of diabetic patients.
    Type: Application
    Filed: October 31, 2006
    Publication date: January 15, 2009
    Applicant: NeuroSearch A/S
    Inventors: Klaus Dugi, Andreas Raschig, Juergen Reess, Frank Berger, Laurence Salin
  • Compounds for the sustained reduction of body weight
    Publication number: 20050203124
    Abstract: The invention relates to the use of a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for a medicament for the for the sustained reduction of body weight.
    Type: Application
    Filed: January 21, 2005
    Publication date: September 15, 2005
    Applicants: Boehringer Ingelheim International GmbH, NeuroSearch A/S
    Inventors: Stephane Pollentier, Andreas Raschig, Juergen Reess, Ole Graff, Birgit Mikkelsen, Morten Priskorn
  • Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an N-methyl-D-aspartate (NMDA) receptors antagonist
    Publication number: 20050182089
    Abstract: Accordingly, the invention relates to a pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and at least one NMDA receptor antagonists or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.
    Type: Application
    Filed: January 21, 2005
    Publication date: August 18, 2005
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Thomas Friedl, Joachim Mierau, Andreas Raschig, Juergen Reess
  • Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
    Publication number: 20050154009
    Abstract: The invention relates to a pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and at least one acetylcholinesterase inhibitor or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.
    Type: Application
    Filed: October 15, 2004
    Publication date: July 14, 2005
    Applicants: Boehringer Ingelheim International GmbH, NeuroSearch A/S
    Inventors: Thomas Friedl, Joachim Mierau, Andreas Raschig, Juergen Reess, Joergen Scheel-Krueger
  • Muscarinic M1 agonist as an inhibitor of beta-amyloid (A&bgr;40 and A&bgr;42)-synthesis
    Patent number: 6573276
    Abstract: Methods of lowering the levels of A&bgr;40, A&bgr;42 and tau protein in a mammal comprising administering to the mammal an effective amount of talsaclidine, or a physiologically acceptable acid addition salt thereof, and methods of treating diseases associated with the formation of diffuse and senile plaques or A&bgr;40-, A&bgr;42- and tau-containing plaques are disclosed.
    Type: Grant
    Filed: April 30, 2002
    Date of Patent: June 3, 2003
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Christoph Hock, Andreas Raschig, Marion Wienrich, Roger Nitsch, Klaus Mendla, Dieter Horst Meier, Klaus Bornemann, Cornelia Dorner-Ciossek
  • Muscarinic M1 agonist as an inhibitor of beta-amyloid (ABeta40 and ABeta42)-synthesis
    Publication number: 20030050221
    Abstract: A method of lowering the levels of A&bgr;40, A&bgr;42, and tau protein in a mammal comprising administering to the mammal an effective amount of talsaclidine or a physiologically acceptable acid addition salt thereof and methods of treating or preventing diseases associated with the formation of diffuse and senile plaques or A&bgr;40-, A&bgr;42- and tau-containing plaques.
    Type: Application
    Filed: April 30, 2002
    Publication date: March 13, 2003
    Inventors: Christoph Hock, Andreas Raschig, Marion Wienrich, Roger Nitsch, Klaus Mendla, Dieter Horst Meier, Klaus Bornemann, Cornelia Dorner-Ciossek